...she told BioCentury. Another CD44 product that was discontinued came from a 2001 deal between GlycoDesign Inc....
...adhesion molecule involved in the regulation of erythropoiesis, cancer and inflammatory diseases, was discontinued when GlycoDesign...

...Friday close of C$0.78, the deal is valued at C$17.2 million (see BioCentury, April 14). GlycoDesign Inc....

...in Redwood City, Calif., location to save $8M next year. $13.8 0.2 $71.1 12/31 4/16/2003 GlycoDesign...

...its previously announced acquisition by Inflazyme Pharmaceuticals Ltd. (TSE:IZP, Richmond, B.C.) (see BioCentury, April 14). GlycoDesign Inc....

...cash. As of Dec. 31, 2002, IZP had about C$22 million ($14.9 million) in cash. GlycoDesign Inc....

...Inflazyme (TSE:IZP) will acquire glycobiology company GlycoDesign (TSE:GD) in a stock deal worth about C$12.8 million...

...the 1999 collaboration, but still wanted to continue to research Core2 inhibitors on its own. GlycoDesign Inc....

...Phase I testing. Data were presented at the American Society of Hematology meeting in Philadelphia. GlycoDesign Inc....

...once-a-day dosing. GD said the drug was well tolerated in both intravenous and subcutaneous forms. GlycoDesign Inc....